Financing strengthens Company’s cash horizon
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that it has obtained €28.7M in non-dilutive financing in the form of two loans from Société Générale and BNP Paribas.
The two loans have an initial term of one year with a five-year extension option. They are 90% guaranteed by the French state as part of the package of measures put in place by the French government to support companies during the COVID-19 pandemic.
“This additional financing provides the opportunity to further strengthen our cash position as well as our research and development activities in France. We thank our bank partners, Société Générale and BNP Paribas, for their support,” said Frederic Lombard, Senior Vice President and Chief Financial Officer, Innate Pharma.
Press Release in English | 202.34 KB |
Communiqué de presse en français | 216.41 KB |